Zacks Research Has Negative View of Chemours FY2025 Earnings

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

The Chemours Company (NYSE:CC - Free Report) - Stock analysts at Zacks Research cut their FY2025 EPS estimates for shares of Chemours in a research note issued to investors on Monday, August 18th. Zacks Research analyst Team now anticipates that the specialty chemicals company will earn $1.30 per share for the year, down from their prior estimate of $1.32. The consensus estimate for Chemours' current full-year earnings is $2.03 per share. Zacks Research also issued estimates for Chemours' Q4 2025 earnings at $0.26 EPS, Q1 2027 earnings at $0.48 EPS and Q2 2027 earnings at $0.75 EPS.

CC has been the topic of a number of other reports. UBS Group lowered their price target on shares of Chemours from $18.00 to $17.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. Wall Street Zen downgraded shares of Chemours from a "hold" rating to a "sell" rating in a report on Wednesday, May 21st. Mizuho raised their target price on shares of Chemours from $13.00 to $16.00 and gave the company an "outperform" rating in a research note on Tuesday, July 15th. Morgan Stanley lowered their target price on shares of Chemours from $22.00 to $15.00 and set an "equal weight" rating on the stock in a research note on Monday, May 12th. Finally, The Goldman Sachs Group lowered their target price on shares of Chemours from $21.00 to $14.00 and set a "neutral" rating on the stock in a research note on Wednesday, May 14th. Five equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $17.38.

Chemours Stock Performance

CC traded up $1.1930 during trading on Tuesday, hitting $15.3430. 4,286,614 shares of the company traded hands, compared to its average volume of 3,584,698. The firm has a market cap of $2.30 billion, a P/E ratio of -5.48 and a beta of 1.61. The stock's fifty day moving average is $12.81 and its 200 day moving average is $12.98. The company has a quick ratio of 0.83, a current ratio of 1.68 and a debt-to-equity ratio of 17.16. Chemours has a one year low of $9.13 and a one year high of $22.38.

Chemours (NYSE:CC - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The specialty chemicals company reported $0.58 earnings per share for the quarter, topping the consensus estimate of $0.46 by $0.12. Chemours had a negative net margin of 7.19% and a positive return on equity of 35.14%. The firm had revenue of $1.62 billion for the quarter, compared to the consensus estimate of $1.57 billion. During the same quarter in the prior year, the company posted $0.38 earnings per share. The business's revenue was up 5.0% on a year-over-year basis. Chemours has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS.

Hedge Funds Weigh In On Chemours

Several large investors have recently modified their holdings of CC. Millennium Management LLC grew its stake in shares of Chemours by 60.4% during the 1st quarter. Millennium Management LLC now owns 4,022,782 shares of the specialty chemicals company's stock valued at $54,428,000 after acquiring an additional 1,515,520 shares during the period. Scopia Capital Management LP grew its stake in shares of Chemours by 71.7% during the 2nd quarter. Scopia Capital Management LP now owns 3,355,261 shares of the specialty chemicals company's stock valued at $38,418,000 after acquiring an additional 1,401,539 shares during the period. Vanguard Group Inc. grew its stake in shares of Chemours by 8.3% during the 1st quarter. Vanguard Group Inc. now owns 16,487,008 shares of the specialty chemicals company's stock valued at $223,069,000 after acquiring an additional 1,263,047 shares during the period. State Street Corp grew its stake in shares of Chemours by 22.7% during the 2nd quarter. State Street Corp now owns 6,114,328 shares of the specialty chemicals company's stock valued at $70,009,000 after acquiring an additional 1,131,682 shares during the period. Finally, Geode Capital Management LLC grew its stake in shares of Chemours by 41.4% during the 2nd quarter. Geode Capital Management LLC now owns 3,484,416 shares of the specialty chemicals company's stock valued at $39,901,000 after acquiring an additional 1,020,933 shares during the period. Hedge funds and other institutional investors own 76.26% of the company's stock.

Insider Buying and Selling at Chemours

In other news, CEO Denise Dignam acquired 4,068 shares of the stock in a transaction on Friday, August 8th. The stock was acquired at an average price of $12.06 per share, with a total value of $49,060.08. Following the completion of the transaction, the chief executive officer owned 191,546 shares of the company's stock, valued at $2,310,044.76. This represents a 2.17% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Damian Gumpel acquired 7,822 shares of the stock in a transaction on Tuesday, June 3rd. The shares were purchased at an average cost of $9.95 per share, with a total value of $77,828.90. Following the transaction, the insider directly owned 131,701 shares of the company's stock, valued at approximately $1,310,424.95. This trade represents a 6.31% increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders purchased 25,290 shares of company stock worth $250,437. 0.47% of the stock is currently owned by company insiders.

Chemours Cuts Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, September 12th. Investors of record on Friday, August 15th will be issued a $0.0875 dividend. The ex-dividend date is Friday, August 15th. This represents a $0.35 annualized dividend and a yield of 2.3%. Chemours's payout ratio is -12.50%.

Chemours Company Profile

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.